Ansbert Gadicke - 27 Aug 2021 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Director, 10%+ Owner
Signature
/s/ Ansbert Gadicke
Issuer symbol
CGEM
Transactions as of
27 Aug 2021
Net transactions value
-$1,476,135
Form type
4
Filing time
31 Aug 2021, 16:48:43 UTC
Previous filing
25 Aug 2021
Next filing
02 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Sale $53,700 -1,846 -0.69% $29.09 264,437 27 Aug 2021 Direct F1, F2
transaction CGEM Common Stock Sale $388,555 -13,357 -0.17% $29.09 7,792,126 27 Aug 2021 See Footnote F1, F2, F3, F4
transaction CGEM Common Stock Sale $125,550 -4,285 -1.6% $29.30 260,152 30 Aug 2021 Direct F1, F5
transaction CGEM Common Stock Sale $908,329 -31,001 -0.4% $29.30 7,761,125 30 Aug 2021 See Footnote F1, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.
F4 The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.